UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 18, 2006
DOV PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
Delaware (State or Other Jurisdiction of Incorporation) | | 000-49730 (Commission File No.) | | 22-3374365 (IRS Employer Identification No.) |
433 Hackensack Avenue, Hackensack, NJ 07601
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, including Area Code: (201) 968-0980
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
ITEM 8.01. OTHER EVENTS.
On May 18, 2006, DOV Pharmaceutical, Inc. (the “Company”) reduced its workforce in order to lower its cost structure as part of a reorganization of operations and to appropriately align the Company’s operations with its current stage of drug development and research.
The reduction in force, which is effective immediately, reduces our workforce to 74 employees from 111 employees. This reduction in force was made as a result of the postponement by us of certain clinical trials and other development activities for bicifadine. On April 24, 2006, we announced that a Phase III clinical trial of bicifadine for the treatment of patients with chronic low back pain did not achieve a statistically significant effect at any of the doses tested.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | DOV Pharmaceutical, Inc. |
|
|
|
| Date: May 19, 2006 | By: | /s/ Leslie Hudson |
| |
Leslie Hudson |
| | President and CEO |
